(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 July 2010 (22.07.2010)

PCT

(10) International Publication Number
WO 2010/083463 A9

(51) International Patent Classification:
G01N 33/569 (2006.01)

(21) International Application Number:
PCT/US2010/021272

(22) International Filing Date:
15 January 2010 (15.01.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/145,029 15 January 2009 (15.01.2009) US

(71) Applicant *(for all designated States except US)*: **LABORATORY CORPORATION OF AMERICA HOLDINGS** [US/US]; 430 South Spring Street, Burlington, North Carolina 27215 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **BATES, Michael** [US/US]; 755 Orange Avenue, San Carlos, California 94070 (US). **COOK, Jennifer, W.** [US/US]; 2605 Garfield Street, San Mateo, California 94403 (US). **DIEDRICH, Gundo** [DE/US]; 832 Grand Avenue, South San Franciso, California 94080 (US). **GOODMAN, Laurie** [US/US]; 236 Del Monte Road, El Granada, California 94018 (US). **MUKHERJEE, Ali** [IN/US]; 443 Lomi-

[Continued on next page]

(54) Title: METHODS OF DETERMINING PATIENT RESPONSE BY MEASUREMENT OF HER-2 EXPRESSION

(57) Abstract: Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.

Figure 1



WO 2010/083463 A9

ta Avenue, Millbrae, California 94030 (US). **PARRY, Gordon** [US/US]; 21 Kingwood Road, Oakland, California 94619 (US). **SPERINDE, Jeff** [US/US]; 623 Isabella Road, El Granada, California 94018-2045 (US). **WILLIAMS, Stephen John** [US/US]; 159 School Street, San Carlos, California 94070 (US).

(74) **Agents**: **CALKINS, Charles, W.** et al.; Kilpatrick Stockton LLP, 1001 West Fourth Street, Winston-Salem, North Carolina 27101 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) **Date of publication of this corrected version**:
23 December 2010

(15) **Information about Correction**:
see Notice of 23 December 2010